FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 572 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... September 12, 2023 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem November 2, 2022 ¿Qué son los biosimilares para el tratamiento del cáncer? November 30, 2021 Load more HOT NEWS 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer Is there a future without Pap testing? Airbrushed Magazines Hurt the Body Image of Young Women — Here’s...
